新型冠状病毒重复感染和应对

doi:10.16138/j.1673-6087.2024.01.05

摘要/Abstract

摘要：

新型冠状病毒（新冠）感染全球形势依然严峻。随着疫情持续发展，重复感染风险显著增加。新冠疫苗接种史、既往感染史、抗体水平、年龄及免疫逃逸等都可以影响重复感染的发生。科学的康复训练能够缓解新冠感染后遗症。疫苗接种仍然是一种重要的预防手段。本文对新冠的流行形势和重复感染现状、重复感染的影响因素以及应对等方面进行讨论，为疫情防控提供借鉴和参考。

关键词: 新型冠状病毒, 重复感染, 新型冠状病毒疫苗, 流行病学

Abstract:

The global situation of the coronavirus disease 2019 (COVID-19) infection remains concerning. As the viruses continue to evolve, the risk of reinfection has markedly increased. COVID-19 vaccination history, previous infection history, antibody titers, age and immune escape can all affect the occurrence of reinfection. Scientific rehabilitation training can help to alleviate post-acute COVID-19 sequalae, and vaccination remains a crucial measure of infection prevention. In the paper, we discussed the current epidemic situation of COVID-19, epidemiology of reinfection and its’ related factors, and strategies to provide reference for epidemic prevention and control.

Key words: COVID-19, Reinfection, COVID-19 vaccines, Epidemiology

中图分类号:

R511

揭志军, 沙家凤, 张萌. 新型冠状病毒重复感染和应对[J]. 内科理论与实践, 2024, 19(01): 25-31.

JIE Zhijun, SHA Jiafeng, ZHANG Meng. Reinfection of COVID-19 and response[J]. Journal of Internal Medicine Concepts & Practice, 2024, 19(01): 25-31.

参考文献 45

[1]	WHO. WHO coronavirus (COVID-19) dashboard[EB/OL]. 2023. https://covid19.who.int/.
[2]	WHO. COVID-19 epidemiological update - 24 November 2023[EB/OL]. 2023. https://www.who.int/publications/m/item/covid-19-epidemiological-update---24-november-2023
[3]	Klaassen F, Chitwood MH, Cohen T, et al. Changes in population immunity against infection and severe disease from severe acute respiratory syndrome coronavirus 2 omicron variants in the United States between December 2021 and November 2022[J]. Clin Infect Dis, 2023, 77(3): 355-361. doi: 10.1093/cid/ciad210 URL
[4]	Bastard J, Taisne B, Figoni J, et al. Impact of the Omicron variant on SARS-CoV-2 reinfections in France, March 2021 to February 2022[J]. Euro Surveill, 2022, 27(13):2200247.
[5]	Guedes AR, Oliveira MS, Tavares BM, et al. Reinfection rate in a cohort of healthcare workers over 2 years of the COVID-19 pandemic[J]. Sci Rep, 2023, 13(1): 712. doi: 10.1038/s41598-022-25908-6 pmid: 36639411
[6]	Eythorsson E, Runolfsdottir HL, Ingvarsson RF, et al. Rate of SARS-CoV-2 reinfection during an Omicron wave in iceland[J]. JAMA Netw Open, 2022, 5(8):e2225320.
[7]	戴映雪, 王瑶, 杜训波, 等. 成都市新冠病毒既往感染者重复感染Omicron变异株情况分析[J]. 中国公共卫生, 2023, 39(4): 442-447.
[8]	Lin M, Cao K, Xu F, et al. A follow-up study on the recovery and reinfection of Omicron COVID-19 patients in Shanghai, China[J]. Emerg Microbes Infect, 2023, 12(2):2261559. doi: 10.1080/22221751.2023.2261559 URL
[9]	Yu W, Guo Y, Hu T, et al. Incidence and severity of SARS-CoV-2 reinfection, a multicenter cohort study in Shanghai, China[J]. J Med Virol, 2023, 95(8):e28997.
[10]	Wang Y, Liang J, Yang H, et al. Epidemiological and clinical characteristics of COVID-19 reinfection during the epidemic period in Yangzhou city, Jiangsu province[J]. Front Public Health, 2023, 11:1256768. doi: 10.3389/fpubh.2023.1256768 URL
[11]	Kissler SM, Hay JA, Fauver JR, et al. Viral kinetics of sequential SARS-CoV-2 infections[EB/J]. medRxiv, 2023. https://www.medrxiv.org/content/10.1101/2023.03.03.23286775v1.
[12]	Hadley E, Yoo YJ, Patel S, et al. SARS-CoV-2 reinfection is preceded by unique biomarkers and related to initial infection timing and severity[EB/J]. medRxiv [Preprint], 2023.https://doi.org/10.1101/2023.01.03.22284042.
[13]	Abu-Raddad LJ, Chemaitelly H, Bertollini R. Severity of SARS-CoV-2 reinfections as compared with primary infections[J]. N Engl J Med, 2021, 385(26):2487-2489. doi: 10.1056/NEJMc2108120 URL
[14]	Mensah AA, Lacy J, Stowe J, et al. Disease severity during SARS-COV-2 reinfection[J]. J Infect, 2022, 84(4):542-550. doi: 10.1016/j.jinf.2022.01.012 URL
[15]	Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection[J]. Nat Med, 2022, 28(11):2398-2405. doi: 10.1038/s41591-022-02051-3 pmid: 36357676
[16]	Cavanaugh AM, Spicer KB, Thoroughman D, et al. Reduced risk of reinfection with SARS-CoV-2 after COVID-19 vaccination - Kentucky, May-June 2021[J]. MMWR Morb Mortal Wkly Rep, 2021, 70(32):1081-1083. doi: 10.15585/mmwr.mm7032e1 URL
[17]	Gazit S, Shlezinger R, Perez G, et al. The incidence of SARS-CoV-2 reinfection in persons with naturally acquired immunity with and without subsequent receipt of a single dose of BNT162b2 vaccine[J]. Ann Intern Med, 2022, 175(5):674-681. doi: 10.7326/M21-4130 URL
[18]	Hammerman A, Sergienko R, Friger M, et al. Effectiveness of the BNT162b2 vaccine after recovery from COVID-19[J]. N Engl J Med, 2022, 386(13):1221-1229. doi: 10.1056/NEJMoa2119497 URL
[19]	Ye C, Zhang G, Zhang A, et al. The Omicron variant reinfection risk among individuals with a previous SARS-CoV-2 infection within one year in Shanghai, China[J]. Vaccines (Basel), 2023, 11(7):1146.
[20]	Cerqueira-Silva T, Andrews JR, Boaventura VS, et al. Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil[J]. Lancet Infect Dis, 2022, 22(6):791-801. doi: 10.1016/S1473-3099(22)00140-2 pmid: 35366959
[21]	COVID-19 Forecasting Team. Past SARS-CoV-2 infection protection against re-infection[J]. Lancet, 2023, 401(10379): 833-842. doi: 10.1016/S0140-6736(22)02465-5 URL
[22]	Powell AA, Kirsebom F, Stowe J, et al. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022[J]. Lancet Infect Dis, 2023, 23(4):435-444. doi: 10.1016/S1473-3099(22)00729-0 URL
[23]	Tan CY, Chiew CJ, Pang D, et al. Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore[J]. Lancet Infect Dis, 2023, 23(7): 799-805. doi: 10.1016/S1473-3099(23)00060-9 URL
[24]	Lumley SF, O'Donnell D, Stoesser NE, et al. Antibody status and incidence of SARS-CoV-2 infection in health care workers[J]. New Engl J Med, 2021, 384(6): 533-540. doi: 10.1056/NEJMoa2034545 URL
[25]	Finch E, Lowe R, Fischinger S, et al. SARS-CoV-2 antibodies protect against reinfection for at least 6 months in a multicentre seroepidemiological workplace cohort[J]. PLoS Biol, 2022, 20(2):e3001531.
[26]	Michlmayr D, Hansen CH, Gubbels SM, et al. Observed protection against SARS-CoV-2 reinfection following a primary infection[J]. Lancet Reg Health Eur, 2022, 20:100452.
[27]	Collier DA, Ferreira IATM, Kotagiri P, et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2[J]. Nature, 2021, 596(7872):417-422. doi: 10.1038/s41586-021-03739-1
[28]	Mazagatos C, Monge S, Olmedo C, et al. Effectiveness of mRNA COVID-19 vaccines in preventing SARS-CoV-2 infections and COVID-19 hospitalisations and deaths in elderly long-term care facility residents, Spain, weeks 53 2020 to 13 2021[J]. Euro Surveill, 2021, 26(24):2100452.
[29]	Palacios-Pedrero MÁ, Jansen JM, Blume C, et al. Signs of immunosenescence correlate with poor outcome of mRNA COVID-19 vaccination in older adults[J]. Nat Aging, 2022, 2(10): 896-905. doi: 10.1038/s43587-022-00292-y pmid: 37118289
[30]	Li M, Peng H, Duan G, et al. Older age and depressive state are risk factors for re-positivity with SARS-CoV-2 Omicron variant[J]. Front Public Health, 2022, 10:1014470. doi: 10.3389/fpubh.2022.1014470 URL
[31]	Hansen CH, Michlmayr D, Gubbels SM, et al. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020[J]. Lancet, 2021, 397(10280):1204-1212. doi: 10.1016/S0140-6736(21)00575-4 URL
[32]	张戈, 张安冉, 贾逸林, 等. 上海市浦东新区新冠病毒重复感染情况分析[EB/J]. 上海预防医学, 2023. https://kns.cnki.net/kcms2/article/abstract?v=smPsKIJgVaAYWg3fyvJbRxd88NUnMspFJv9V6LXB6zr56O7fU8X9zY_z9gu0Ik51p3j_gyp3zac8piy_F_GNfPIjzWO2LFZzmAOYZGc1hudgNqVcywJPPuGjKAxFH_7YyCFtLrc86OE=&uniplatform=NZKPT&language=CHS.
[33]	Washington State Department of Health. Reported COVID-19 reinfections in Washington State[EB/OL]. 2022. https://doh.wa.gov/sites/default/files/2022-02/421-024-ReportedReinfections.pdf.
[34]	Ferguson N, Ghani A, Cori A, et al. Growth, population distribution and immune escape of Omicron in England[EB/OL]. 2021. https://www.imperial.ac.uk/media/imperial-college/medicine/mrc-gida/2021-12-16-COVID19-Report-49.pdf.
[35]	Chen X, Xu Y, Xie Y, et al. Protective effect of plasma neutralization from prior SARS-CoV-2 Omicron infection against BA.5 subvariant symptomatic reinfection[J]. Lancet Reg Health West Pac, 2023, 33:100758.
[36]	陆婉莹, 陈鑫华, 郑楠, 等. 新型冠状病毒原型株有症状感染者中和抗体水平对奥密克戎亚型BA.1、BA.4和BA.5的保护概率预测[J]. 中华医学杂志, 2023, 103(18): 1429-1434.
[37]	Altarawneh HN, Chemaitelly H, Ayoub HH, et al. Protective effect of previous SARS-CoV-2 infection against Omicron BA.4 and BA.5 subvariants[J]. N Engl J Med, 2022, 387(17):1620-1622. doi: 10.1056/NEJMc2209306 URL
[38]	Chemaitelly H, Tang P, Coyle P, et al. Protection against reinfection with the Omicron BA.2.75 subvariant[J]. N Engl J Med, 2023, 388(7):665-667. doi: 10.1056/NEJMc2214114 URL
[39]	Chen JJ, Li LB, Peng HH, et al. Neutralization against XBB.1 and XBB.1.5 after Omicron subvariants breakthrough infection or reinfection[J]. Lancet Reg Health West Pac, 2023, 33:100759.
[40]	Paliani U, Cardona A, Gili A, et al. Impact of rehabilitation treatment during the acute phase of SARS-CoV-2 infection[EB/J]. Eur J Intern Med, 2023. https://www.ejinme.com/article/S0953-6205(23)00415-6/abstract.
[41]	de Araújo Furtado PL, do Socorro Brasileiro-Santos M, de Mello BLC, et al. The effect of telerehabilitation on physical fitness and depression/anxiety in post-COVID-19 patients[J]. Int J Telerehabil, 2023, 15(1):e6560.
[42]	WHO. Support for rehabilitation: self-management after COVID-19-related illness, second edition 2021[EB/OL]. 2021. https://iris.who.int/handle/10665/344472.
[43]	国务院联防联控机制综合组. 《近期重点人群新冠病毒疫苗接种工作方案》解读[EB/OL]. http://www.nhc.gov.cn/xcs/zhengcwj/202307/d5968788cfee4caf8087955d470fd306.shtml.
[44]	Tan ST, Kwan AT, Rodríguez-Barraquer I, et al. Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave[J]. Nat Med, 2023, 29(2):358-365. doi: 10.1038/s41591-022-02138-x pmid: 36593393
[45]	Cromer D, Juno JA, Khoury D, et al. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection[J]. Nat Rev Immunol, 2021, 21(6): 395-404. doi: 10.1038/s41577-021-00550-x pmid: 33927374